Molecularly targeted therapies for breast cancer

Timothy James Hobday, Edith A. Perez

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: The management of patients with localized and advanced breast cancer continues to evolve. Chemotherapy, endocrine therapy, and trastuzumab are effective therapies but leave considerable room for improvement. As the cellular aberrations inherent to cancer cells in general and breast cancer cells specifically are better understood, therapies to target specific cellular pathways continue to be developed with the goal of expanding available effective therapy through better patient selection. Methods: We conducted a computerized search of the medical literature as well as a manual search of selected meeting abstracts. Results: Several targeted therapies are in phase III clinical trials testing their promise in the treatment of breast cancer. Many other agents are completing phase I and II testing. An overview of the most promising agents in clinical development is discussed herein. Conclusions: Targeted therapy for breast cancer is a reality at this time, and several new agents hold promise for expanding and refining the pool of patients likely to further benefit from this approach in the near future.

Original languageEnglish (US)
Pages (from-to)73-81
Number of pages9
JournalCancer Control
Volume12
Issue number2
StatePublished - Apr 2005

Fingerprint

Breast Neoplasms
Therapeutics
Phase III Clinical Trials
Patient Selection
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Molecularly targeted therapies for breast cancer. / Hobday, Timothy James; Perez, Edith A.

In: Cancer Control, Vol. 12, No. 2, 04.2005, p. 73-81.

Research output: Contribution to journalArticle

Hobday, TJ & Perez, EA 2005, 'Molecularly targeted therapies for breast cancer', Cancer Control, vol. 12, no. 2, pp. 73-81.
Hobday, Timothy James ; Perez, Edith A. / Molecularly targeted therapies for breast cancer. In: Cancer Control. 2005 ; Vol. 12, No. 2. pp. 73-81.
@article{2a26035e9326442a8cae17e8a96b0b12,
title = "Molecularly targeted therapies for breast cancer",
abstract = "Background: The management of patients with localized and advanced breast cancer continues to evolve. Chemotherapy, endocrine therapy, and trastuzumab are effective therapies but leave considerable room for improvement. As the cellular aberrations inherent to cancer cells in general and breast cancer cells specifically are better understood, therapies to target specific cellular pathways continue to be developed with the goal of expanding available effective therapy through better patient selection. Methods: We conducted a computerized search of the medical literature as well as a manual search of selected meeting abstracts. Results: Several targeted therapies are in phase III clinical trials testing their promise in the treatment of breast cancer. Many other agents are completing phase I and II testing. An overview of the most promising agents in clinical development is discussed herein. Conclusions: Targeted therapy for breast cancer is a reality at this time, and several new agents hold promise for expanding and refining the pool of patients likely to further benefit from this approach in the near future.",
author = "Hobday, {Timothy James} and Perez, {Edith A.}",
year = "2005",
month = "4",
language = "English (US)",
volume = "12",
pages = "73--81",
journal = "Cancer Control",
issn = "1073-2748",
publisher = "H. Lee Moffitt Cancer Center and Research Institute",
number = "2",

}

TY - JOUR

T1 - Molecularly targeted therapies for breast cancer

AU - Hobday, Timothy James

AU - Perez, Edith A.

PY - 2005/4

Y1 - 2005/4

N2 - Background: The management of patients with localized and advanced breast cancer continues to evolve. Chemotherapy, endocrine therapy, and trastuzumab are effective therapies but leave considerable room for improvement. As the cellular aberrations inherent to cancer cells in general and breast cancer cells specifically are better understood, therapies to target specific cellular pathways continue to be developed with the goal of expanding available effective therapy through better patient selection. Methods: We conducted a computerized search of the medical literature as well as a manual search of selected meeting abstracts. Results: Several targeted therapies are in phase III clinical trials testing their promise in the treatment of breast cancer. Many other agents are completing phase I and II testing. An overview of the most promising agents in clinical development is discussed herein. Conclusions: Targeted therapy for breast cancer is a reality at this time, and several new agents hold promise for expanding and refining the pool of patients likely to further benefit from this approach in the near future.

AB - Background: The management of patients with localized and advanced breast cancer continues to evolve. Chemotherapy, endocrine therapy, and trastuzumab are effective therapies but leave considerable room for improvement. As the cellular aberrations inherent to cancer cells in general and breast cancer cells specifically are better understood, therapies to target specific cellular pathways continue to be developed with the goal of expanding available effective therapy through better patient selection. Methods: We conducted a computerized search of the medical literature as well as a manual search of selected meeting abstracts. Results: Several targeted therapies are in phase III clinical trials testing their promise in the treatment of breast cancer. Many other agents are completing phase I and II testing. An overview of the most promising agents in clinical development is discussed herein. Conclusions: Targeted therapy for breast cancer is a reality at this time, and several new agents hold promise for expanding and refining the pool of patients likely to further benefit from this approach in the near future.

UR - http://www.scopus.com/inward/record.url?scp=18444394024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18444394024&partnerID=8YFLogxK

M3 - Article

C2 - 15855890

AN - SCOPUS:18444394024

VL - 12

SP - 73

EP - 81

JO - Cancer Control

JF - Cancer Control

SN - 1073-2748

IS - 2

ER -